Search results for "Demyelinating Diseases"

showing 8 items of 28 documents

How to treat tumefactive demyelinating disease?

2013

Glioma-like inflammatory demyelinating lesions can be found in patients with pre-diagnosed multiple sclerosis, but they have also been described as an isolated disease entity. The initial diagnostic work-up usually includes a biopsy for histopathological analysis. However, even after unambiguous histopathologic classification, tumefactive lesions pose a therapeutic challenge. Until now, there have been no guidelines on how to treat patients with these rare and extreme lesion phenotypes. Here we report a patient with a relapsing unifocal tumefactive demyelinating lesion. The patient initially showed a good response to steroid treatment, with full clinical recovery. However, after relapse of…

Malemedicine.medical_specialtyPathologyTime FactorsBiopsymedicine.medical_treatmentDrug Administration ScheduleLesionRecurrenceInduction therapyBiopsymedicineDemyelinating diseaseHumansIn patientmedicine.diagnostic_testDrug Substitutionbusiness.industryMultiple sclerosisImmunosuppressionMiddle Agedmedicine.diseaseMagnetic Resonance ImagingRegimenTreatment OutcomeNeurologyDrug Therapy CombinationSteroidsNeurology (clinical)Radiologymedicine.symptombusinessImmunosuppressive AgentsDemyelinating DiseasesMultiple Sclerosis Journal
researchProduct

Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study

2021

Background and purpose: Tumefactive multiple sclerosis (TuMS) (i.e., MS onset presenting with tumefactive demyelinating lesions [TDLs]) is a diagnostic and therapeutic challenge. We performed a multicentre retrospective study to describe the clinical characteristics and the prognostic factors of TuMS. Methods: One hundred two TuMS patients were included in this retrospective study. Demographic, clinical, magnetic resonance imaging (MRI), laboratory data and treatment choices were collected. Results: TuMS was found to affect women more than men (female:male: 2.4), with a young adulthood onset (median age: 29.5 years, range: 11–68 years, interquartile range [IQR]: 38 years). At onset, 52% of …

Maletumefactive demyelinating lesions (TDLs)0302 clinical medicineRetrospective StudieInterquartile rangedifferential diagnosis030212 general & internal medicineProspective StudiesYoung adultProspective cohort studyChildtreatmentTumefactive multiple sclerosiTumefactive demyelinating lesionsDemyelinating DiseaseMiddle AgedMagnetic Resonance ImagingDifferential diagnosis Multiple sclerosis Tumefactive demyelinating lesions Tumefactive multiple sclerosisNeurologydifferential diagnosis; Multiple sclerosis; Tumefactive demyelinating lesions; Tumefactive multiple sclerosisFemaleHumanAdultmedicine.medical_specialtyMultiple SclerosisAdolescentdifferential diagnosiSettore MED/26Multiple sclerosis03 medical and health sciencesYoung AdultTumefactive multiple sclerosisOligoclonal BandInternal medicinemedicineHumansMultiple sclerosiTumefactive multiple sclerosisTumefactive multiple sclerosis (TuMS)AgedRetrospective StudiesTumefactive demyelinating lesionExpanded Disability Status Scalebusiness.industryOligoclonal BandsRetrospective cohort studyOdds ratiomedicine.diseaseConfidence intervalProspective Studiedifferential diagnosis; Multiple sclerosis; Tumefactive demyelinating lesions; Tumefactive multiple sclerosis; Adolescent; Adult; Aged; Child; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Oligoclonal Bands; Prospective Studies; Retrospective Studies; Young Adult; Demyelinating Diseases; Multiple SclerosisprognosisNeurology (clinical)business030217 neurology & neurosurgeryDemyelinating Diseases
researchProduct

Cerebrospinal Fluid Analysis in Multiple Sclerosis Diagnosis: An Update

2019

Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the central nervous system (CNS) with brain neurodegeneration. MS patients present heterogeneous clinical manifestations in which both genetic and environmental factors are involved. The diagnosis is very complex due to the high heterogeneity of the pathophysiology of the disease. The diagnostic criteria have been modified several times over the years. Basically, they include clinical symptoms, presence of typical lesions detected by magnetic resonance imaging (MRI), and laboratory findings. The analysis of cerebrospinal fluid (CSF) allows an evaluation of inflammatory processes circumscribed to the CNS and reflects chan…

Medicine (General)Pathologymedicine.medical_specialtyMultiple SclerosisCentral nervous systemDiseaseReviewcerebrospinal fluiddemyelinating diseaseR5-920Cerebrospinal fluidmedicineDemyelinating diseaseoligoclonal banddemyelinating diseasesHumansimmunoglobulin light chainmedicine.diagnostic_testbusiness.industryMultiple sclerosisoligoclonal bandsbiomarkersMagnetic resonance imagingGeneral MedicineGold standard (test)medicine.diseasePathophysiologyimmunoglobulin light chainsmedicine.anatomical_structuremultiple sclerosiDisease ProgressionbiomarkerbusinessMedicina
researchProduct

Remyelinating strategies in multiple sclerosis.

2014

Multiple sclerosis (MS) is the most common chronic inflammatory demyelinating disorder of the CNS characterized by infiltration of immune cells and progressive damage to myelin sheaths and neurons. In recent years, the importance of the neuronal compartment in the early pathology of multiple sclerosis has become increasingly clear. Direct axonal damage within the early stages of inflammation as well as neuronal injury as a result of chronic demyelination are essential factors for the development of long-term disability in patients. Viewing MS as both inflammatory and neurodegenerative has significant implications for treatment, with remyelination of denuded axons to protect neurons from dam…

Multiple SclerosisInflammationBiologyNeuroprotectionImmune systemmedicineHumansPharmacology (medical)RemyelinationDemyelinating DisorderMyelin SheathNeuronsGeneral NeuroscienceMultiple sclerosisNeurodegenerationmedicine.diseaseAxonsPathology of multiple sclerosisOligodendrogliamedicine.anatomical_structurenervous systemImmunologyNeurology (clinical)medicine.symptomNeuroscienceImmunosuppressive AgentsDemyelinating DiseasesExpert review of neurotherapeutics
researchProduct

Demyelination patterns in a mathematical model of multiple sclerosis.

2016

In this paper we derive a reaction-diffusion-chemotaxis model for the dynamics of multiple sclerosis. We focus on the early inflammatory phase of the disease characterized by activated local microglia, with the recruitment of a systemically activated immune response, and by oligodendrocyte apoptosis. The model consists of three equations describing the evolution of macrophages, cytokine and apoptotic oligodendrocytes. The main driving mechanism is the chemotactic motion of macrophages in response to a chemical gradient provided by the cytokines. Our model generalizes the system proposed by Calvez and Khonsari (Math Comput Model 47(7–8):726–742, 2008) and Khonsari and Calvez (PLos ONE 2(1):e…

Multiple Sclerosismedicine.medical_treatmentInflammationApoptosisBiology01 natural sciencesModels BiologicalConcentric ring03 medical and health sciences0302 clinical medicineTuring instabilitymedicineHumansMultiple sclerosi0101 mathematicsSettore MAT/07 - Fisica MatematicaInflammationMicrogliaOligodendrocyte apoptosisPatternMultiple sclerosisTuring instabilityApplied MathematicsChemotaxismedicine.diseaseAgricultural and Biological Sciences (miscellaneous)Magnetic Resonance Imaging010101 applied mathematicsChemotaxis PDE modelCytokinemedicine.anatomical_structureModeling and SimulationImmunologymedicine.symptomNeuroscience030217 neurology & neurosurgeryDemyelinating DiseasesJournal of mathematical biology
researchProduct

Prognostic indicators in pediatric clinically isolated syndrome

2017

To assess prognostic factors for a second clinical attack and a first disability worsening event in pediatric clinically isolated syndrome (pCIS) suggestive of Multiple Sclerosis (MS) patients. Objective: To assess prognostic factors for a second clinical attack and a first disability-worsening event in pediatric clinically isolated syndrome (pCIS) suggestive of multiple sclerosis (MS) patients. Methods: A cohort of 770 pCIS patients was followed up for at least 10 years. Cox proportional hazard models and Recursive Partitioning and Amalgamation (RECPAM) tree-regression were used to analyze data. Results: In pCIS, female sex and a multifocal onset were risk factors for a second clinical att…

RegistrieMaleMultiple SclerosisAdolescentAdolescent; Age of Onset; Child; Demyelinating Diseases; Female; Follow-Up Studies; Humans; Male; Multiple Sclerosis; Prognosis; Retrospective Studies; Risk Factors; Disease Progression; Registries; Neurology; Neurology (clinical)PrognosiONSET MULTIPLE-SCLEROSISCHILDHOODCHILDRENPARACLINICAL FEATURESDISABILITY PROGRESSIONNOFollow-Up StudieRisk FactorsRetrospective Studieprognostic indicatorsMultiple Sclerosipediatric multiple sclerosis prognosis indicatorsHumansRegistriesAge of OnsetChildOPTIC NEURITISRetrospective StudiesRisk FactorDemyelinating DiseaseNATURAL-HISTORYPrognosismultiple sclerosis clinically isolated syndrome prognostic indicatorsNeurologyTRANSVERSE MYELITISclinically isolated syndromeINTERFERON BETA-1BDisease ProgressionSettore MED/26 - NeurologiaFemaleNeurology (clinical)FOLLOW-UPDemyelinating DiseasesFollow-Up StudiesHuman
researchProduct

The actual state of computerized tomography (CT)-computer assisted tomography (CAT).

1977

medicine.medical_specialtyBrain Diseasesbusiness.industryBrain NeoplasmsComputer assisted tomographyBrainDiagnosis DifferentialCerebrovascular DisordersNeurologySpinal CordBrain InjuriesmedicineHumansMedical physicsSpinal DiseasesNeurology (clinical)RadiologyTomographyState (computer science)businessPneumoencephalographyTomography X-Ray ComputedNeuroradiologyDemyelinating DiseasesHydrocephalusJournal of neurology
researchProduct

Answer to: The possible risk of cancer in multiple sclerosis patients: a controversial issue

2010

medicine.medical_specialtyMultiple Sclerosis | Demyelinating Diseases | concentric sclerosisNeurologybusiness.industryMultiple sclerosisPhysical therapyMedicineCancerSettore MED/26 - NeurologiaNeurology (clinical)businessIntensive care medicinemedicine.diseaseEuropean Journal of Neurology
researchProduct